An Open-Label, Extension Study of the Effects of TRx0237 in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)
Phase of Trial: Phase III
Latest Information Update: 03 Jul 2019
Price : $35 *
At a glance
- Drugs Hydromethylthionine mesylate (Primary)
- Indications Alzheimer's disease; Dementia
- Focus Adverse reactions; Registrational
- Sponsors TauRx Therapeutics
- 02 Jul 2019 The trial is discontinued at UK (08 May 2017), as per European Clinical Trials Database record.
- 12 Mar 2018 Status changed from recruiting to discontinued.
- 02 Aug 2017 This trial has been discontinued in Netherlands.